Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
ELUTIA INC. President and CEO C. Randal Mills reported compensation-related equity activity involving restricted stock units that vested into Class A Common Stock. On this vesting, 22,473 shares were issued upon conversion of restricted stock units, and 8,064 of those shares were withheld by the company to cover tax obligations. These transactions were recorded as an option-style exercise and a tax-withholding disposition rather than open-market buying or selling. After the transactions, Mills directly held 441,180 shares of Class A Common Stock, indicating he retained most of the newly vested shares as ongoing equity exposure.
Elutia Inc. reported results of its 2026 annual stockholder meeting and an approved change to its long-term incentive plan. Stockholders approved a First Amendment to the Amended and Restated 2020 Incentive Award Plan, adding authorization for an additional 3,000,000 shares of Class A common stock for awards, extending the plan’s annual share increase feature through January 1, 2036 and moving the plan termination date to the tenth anniversary of the April 22, 2026 amendment date.
All other proposals passed, including election of two Class III directors to terms ending in 2029, ratification of PricewaterhouseCoopers LLP as auditor for 2026, and advisory approval of executive compensation. Stockholders also advised holding future say-on-pay votes every year, and the board chose an annual frequency accordingly.
Elutia Inc. director and ten percent owner Kevin Rakin reported receiving a grant of stock options covering 159,590 shares of Class A Common Stock at an exercise price of $0.96 per share. The options vest on the earlier of the day before the first annual meeting after grant or the first anniversary, subject to his continued board service, and expire on June 11, 2036. Following this award, he holds 159,590 derivative securities directly.
ELUTIA INC. director David Colpman received a grant of stock options covering 106,393 shares of Class A Common Stock at an exercise price of $0.96 per share. The grant is compensation, not an open-market trade, and was awarded at no cost to him.
These options vest and become exercisable on the earlier of the day immediately preceding Elutia’s first annual meeting following the grant date or the first anniversary of the grant date, provided he continues serving on the board through the vesting date. The options expire on June 11, 2036.
ELUTIA INC. director Guido J. Neels received a grant of stock options covering 106,393 shares of Class A common stock. The options have an exercise price of $0.96 per share and expire on June 11, 2036.
The grant was made automatically under the company’s Non-Employee Director Compensation Program. These options vest and become exercisable on the earlier of the day immediately preceding the company’s first annual meeting following the grant date or the first anniversary of the grant date, if he continues serving on the board.
ELUTIA INC. director Brigid Makes reported receiving a stock option grant as part of the company’s Non-Employee Director Compensation Program. The award covers 106,393 shares of Class A common stock at an exercise price of $0.9600 per share and expires on June 11, 2036. The option vests and becomes exercisable on the earlier of the day immediately preceding Elutia’s first annual meeting following the grant date or the first anniversary of the grant date, subject to her continued service on the board. This is a compensation-related grant and not an open-market share purchase.
ELUTIA INC. Chief Scientific Officer Michelle LeRoux Williams reported routine equity compensation activity. On June 10, 2026, 12,500 restricted stock units vested into Class A Common Stock, and 4,269 shares were withheld at $1.04 per share to cover tax obligations. Following these transactions, she directly holds 122,321 Class A shares and 25,000 restricted stock units, from an original grant of 150,000 units awarded on January 31, 2024 with a scheduled vesting through December 10, 2026.
ELUTIA INC. chief financial officer Matthew Ferguson reported routine equity compensation activity involving restricted stock units that vested into Class A common stock. On the vesting date, 12,500 RSUs converted into 12,500 shares of Class A common stock, as each unit represents one share.
The company withheld 4,485 of these shares at an implied price of $1.04 per share to cover tax withholding obligations, which is recorded as a disposition but not an open-market sale. After these transactions, Ferguson directly owned 484,567 shares of Class A common stock and held 25,000 restricted stock units as of the report.
ELUTIA INC. President and CEO C. Randal Mills reported routine equity compensation activity tied to restricted stock units (RSUs). On June 10, 2026, 27,083 RSUs converted into an equal number of Class A common shares, reflecting a scheduled vesting.
To satisfy tax withholding on this vesting, the issuer withheld 9,718 Class A shares at an indicated value of $1.04 per share, a disposition categorized as payment of tax liability rather than an open-market sale. Following these transactions, Mills directly holds 436,489 Class A shares and 216,666 RSUs.
Footnotes explain that these RSUs were part of a 487,500-unit grant made on January 31, 2024. RSUs covering 162,500 shares vest only if the stock trades at or above $6.00, $10.00, $14.00 and $18.00 for twenty consecutive trading days, while 325,000 time-based RSUs vest on a specified schedule through December 10, 2026, subject to Mills’ continued employment.
ELUTIA INC. director and ten percent owner Kevin Rakin, together with affiliated HighCape entities, reported internal share movements rather than market trades in Class A Common Stock. On June 1, a bona fide gift transferred 70,000 shares, leaving 126,120 shares held directly afterward. A separate 50,000-share transaction reflects a distribution by trusts to their beneficiaries without payment of consideration, with 272,419 shares then held indirectly through trusts. An additional 4,706,559 shares are reported as indirectly held through HighCape investment entities. Footnote disclosures state that Mr. Rakin and the HighCape reporting persons may be deemed to beneficially own these indirect holdings but each disclaims beneficial ownership except to the extent of any pecuniary interest.